Crizanlizumab

Last Updated: 11/08/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 155 publications

Precision Medicine in Sickle Cell Disease: From Molecular Pathways to Curative Strategies.

Precision Medicine in Sickle Cell Disease: From Molecular Pathways to Curative Strategies.

Journal: Hemoglobin

Published: October 15, 2026

Brain MRI and cognitive outcomes in adults with sickle cell disease treated with crizanlizumab.

Brain MRI and cognitive outcomes in adults with sickle cell disease treated with crizanlizumab.

Journal: Blood red cells & iron

Published: October 06, 2026

Endothelin receptor antagonism in sickle cell disease: Is the time now?

Endothelin receptor antagonism in sickle cell disease: Is the time now?

Journal: Canadian journal of physiology and pharmacology

Published: September 10, 2026

Endothelin Receptor Antagonism in Sickle Cell Disease: Is the Time Now?

Endothelin Receptor Antagonism in Sickle Cell Disease: Is the Time Now?

Journal: Canadian journal of physiology and pharmacology

Published: September 10, 2026

crizanlizumab and inclacumab are equally potent inhibitors of cell adhesion in the blood of patients with sickle cell disease.

crizanlizumab and inclacumab are equally potent inhibitors of cell adhesion in the blood of patients with sickle cell disease.

Journal: Blood. Red cells & iron

Published: August 30, 2026

L-Glutamine for Pediatric Sickle Cell Disease: Pharmacology, Mechanism of Action, Safety and Efficacy.

L-Glutamine for Pediatric Sickle Cell Disease: Pharmacology, Mechanism of Action, Safety and Efficacy.

Journal: In vivo (Athens, Greece)

Published: August 07, 2026

Association between comorbid depression, antidepressant adherence, and disease-modifying therapy adherence among Texas Medicaid patients with sickle cell disease.

Association between comorbid depression, antidepressant adherence, and disease-modifying therapy adherence among Texas Medicaid patients with sickle cell disease.

Journal: Journal of managed care & specialty pharmacy

Published: June 24, 2026

Benefit-risk of voxelotor, crizanlizumab, and l-glutamine in sickle cell disease: A systematic review.

Benefit-risk of voxelotor, crizanlizumab, and l-glutamine in sickle cell disease: A systematic review.

Journal: The American journal of the medical sciences

Published: June 17, 2026

Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway.

Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway.

Journal: Cancer research communications

Published: May 19, 2026

A Multicenter, Open-Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST).

A Multicenter, Open-Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST).

Journal: American journal of hematology

Published: February 11, 2026

Rethinking Sickle Cell Disease as a Systemic Vasculopathy.

Rethinking Sickle Cell Disease as a Systemic Vasculopathy.

Journal: Cells

Published: January 02, 2026

Optimizing the right time to start sickle cell therapies.

Optimizing the right time to start sickle cell therapies.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Showing 1-12 of 155

Last Updated: 11/08/2026